Imsidolimab

Phase 2Monoclonal antibody

VVanda Pharmaceuticals

Imsidolimab is one of 64 small molecule programs targeting Palmoplantar Pustulosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Palmoplantar PustulosisActive, not recruiting

IchthyosisActive, not recruiting

Hidradenitis SuppurativaActive, not recruiting

Generalized Pustular PsoriasisActive, not recruiting

Palmoplantar PustulosisPhase 2

Active, not recruiting

IchthyosisPhase 2

Active, not recruiting

Hidradenitis SuppurativaPhase 2

Active, not recruiting

Generalized Pustular PsoriasisPhase 2

Active, not recruiting

Competition

Competitive Landscape

100 competitors in Hidradenitis Suppurativa

#DrugCompanyPhaseTrials

Cosentyx

Novartis

Phase 3

7 2

Bimzelx

UCB

Phase 3

5 3

Jakafi

Incyte

Phase 3

4 4

Rhapsido

Novartis

Phase 3

3 5

Rinvoq

AbbVie

Phase 3

2 6

Taltz

Lutikizumab

3 8

Povorcitinib

Incyte

Phase 3

3 9

Tremfya

Johnson & Johnson

Phase 2

3 10

Otezla

Amgen

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Efficacy and Safety3 trials

A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Acne Vulgaris

Completed·VVanda Pharmaceuticals·Phase 2·NCT04856917·123 enrolled

Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPP

Completed·VVanda Pharmaceuticals·Phase 3·NCT05352893·45 enrolled

A Study to Evaluate of the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Acneiform Rash

Terminated·VVanda Pharmaceuticals·Phase 2·NCT04697069·4 enrolled

Generalized Pustular Psoriasis2 trials

Long-Term Safety and Efficacy of Imsidolimab (ANB019) in Subjects With Generalized Pustular Psoriasis

Terminated·VVanda Pharmaceuticals·Phase 3·NCT05366855·42 enrolled

A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Generalized Pustular Psoriasis

Completed·VVanda Pharmaceuticals·Phase 2·NCT03619902·8 enrolled

Ichthyosis1 trial

A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Ichthyosis

Terminated·VVanda Pharmaceuticals·Phase 2·NCT04697056·5 enrolled

Palmoplantar Pustulosis1 trial

A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Palmoplantar Pustulosis

Completed·VVanda Pharmaceuticals·Phase 2·NCT03633396·59 enrolled

Hidradenitis Suppurativa1 trial

A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Hidradenitis Suppurativa

Completed·VVanda Pharmaceuticals·Phase 2·NCT04856930·149 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Imsidolimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Imsidolimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Imsidolimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Vanda Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: VVanda Pharmaceuticals

Imsidolimab

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Efficacy and Safety3 trials

Generalized Pustular Psoriasis2 trials

Ichthyosis1 trial

Palmoplantar Pustulosis1 trial

Hidradenitis Suppurativa1 trial

References

Drug Info

Quick Facts

Related News